Drug Trial Radar · NCT01486628
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Apr 30, 2012
Primary completion
Nov 22, 2012
Study completion Jun 13, 2013
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 6, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in healthy volunteers. Objectives are to determine: 1. the maximal tolerated dose of SC ND-0612 2. the steady state plasma concentration of LD and CD following SC ND-0612 administration. Each treatment group will include 6 healthy volunteers. Dosing will be done in a sequential manner.
Conditions
- Parkinson's Disease
Interventions
ND0612Drug
levodopa and carbidopa solution for subcutaneous administration
PlaceboDrug
Saline solution for SC continuous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah Medical Center
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.